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1654Objectives: Ischemia–reperfusion injury contributes significantly to morbidity and mortality in lung transplant
patients. Currently, no therapeutic agents are clinically available to prevent ischemia–reperfusion injury, and
treatment strategies are limited to maintaining oxygenation and lung function. Adenosine can modulate inflam-
matory activity and injury by binding to various adenosine receptors; however, the role of the adenosine A1 re-
ceptor in ischemia–reperfusion injury and inflammation is not well understood. The present study tested the
hypothesis that selective, exogenous activation of the A1 receptor would be anti-inflammatory and attenuate
lung ischemia–reperfusion injury.
Methods:Wild-type and A1 receptor knockout mice underwent 1 hour of left lung ischemia and 2 hours of re-
perfusion using an in vivo hilar clamp model. An A1 receptor agonist, 2-chloro-N6-cyclopentyladenosine, was
administered 5 minutes before ischemia. After reperfusion, lung function was evaluated by measuring airway
resistance, pulmonary compliance, and pulmonary artery pressure. The wet/dry weight ratio was used to assess
edema. The myeloperoxidase and cytokine levels in bronchoalveolar lavage fluid were measured to determine
the presence of neutrophil infiltration and inflammation.
Results: In the wild-type mice, 2-chloro-N6-cyclopentyladenosine significantly improved lung function and at-
tenuated edema, cytokine expression, and myeloperoxidase levels compared with the vehicle-treated mice after
ischemia–reperfusion. The incidence of lung ischemia–reperfusion injury was similar in the A1 receptor knock-
out and wild-type mice; and 2-chloro-N6-cyclopentyladenosine had no effects in the A1 receptor knockout mice.
In vitro treatment of neutrophils with 2-chloro-N6-cyclopentyladenosine significantly reduced chemotaxis.
Conclusions: Exogenous A1 receptor activation improves lung function and decreases inflammation, edema,
and neutrophil chemotaxis after ischemia and reperfusion. These results suggest a potential therapeutic appli-
cation for A1 receptor agonists for the prevention of lung ischemia–reperfusion injury after transplantation.
(J Thorac Cardiovasc Surg 2013;145:1654-9)Ischemia–reperfusion (IR) injury and its more severe form,
primary graft dysfunction, lead to significant morbidity and
mortality after lung transplantation, with mortality rates ap-
proaching 40%. Ischemia is unavoidable during transplan-
tation, and the subsequent effect of reperfusion results in
significant cellular damage, oxidative stress, innate immune
responses, and lung inflammation.1,2 During organ
inflammation and IR injury, such as after transplantation,
adenosine is a retaliatory metabolite released from many
cell sources and serves largely as a protective agent with
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The Journal of Thoracic and Cardiovascular Surthrough binding of 4 different G protein-coupled receptors:
A1 receptor (A1R), A2AR, A2BR, and A3R, and adenosine
receptor signaling typically entails second messenger path-
ways such as the cyclic adenosine monophosphate-
dependent protein kinase A pathway or the phospholipase
C pathway.
All 4 adenosine receptors are expressed in the lungs of
mice3 and humans.4 Studies from our laboratory have sug-
gested that activation of A1R or A3R, by selective agonists,
offers protection from lung IR injury in an isolated rabbit
lung model.5 We have also demonstrated potent anti-
inflammatory effects of A2AR activation in both a mouse
lung IR model6 and a porcine lung transplant model.7 How-
ever, our studies suggested a proinflammatory role for the
A2BR in the setting of lung IR.
8 The role of the A1R in
lung IR injury remains controversial and not well under-
stood. The A1R is expressed largely on endothelial, epithe-
lial, and inflammatory cells and signals through Gi or G0
proteins. Its effects include inhibition of adenylyl cyclase,
activation of Kþ channels, inhibition of N-, P-, and
Q-type Caþ channels, and activation of phospholipase Cb.9
Earlier studies reported that A1R antagonism attenuates
lung inflammation after IR.10 However, more recent studies,gery c June 2013
Abbreviations and Acronyms
A1R/ ¼ congenic A1 receptor knockout
BAL ¼ bronchoalveolar lavage
CCPA ¼ 2-chloro-N6-cyclopentyladenosine
FBS ¼ fetal bovine serum
IR ¼ ischemia–reperfusion
MPO ¼ myeloperoxidase
TNF-a ¼ tumor necrosis factor-a
WT ¼ wild-type
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Xincluding our own, have suggested that A1R activation has
protective effects in several models of inflammatory lung
injury.5,11,12 Using A1R knockout mice and a specific
pharmacologic A1R agonist, the present study tested the
hypothesis that specific A1R activation would be anti-
inflammatory and provide significant protection against
lung IR injury.
METHODS
Animals and Study Design
Adult male C57BL/6 wild-type (WT) mice (Jackson Laboratories, Bar
Harbor, Me) and congenic A1R knockout (A1R/) mice 8 to 12 weeks
old were used. The A1R/ mice13 were a gift of Dr Jurgen Schnermann
(Institute of Pharmacology and Toxicology, University of T€ubingen,
T€ubingen, Germany). The mice underwent either sham or IR surgery
(n ¼ 6 mice/group). The mice were randomly allocated to the various con-
trol and experimental groups. They were treated with either vehicle (0.1%
dimethyl sulfoxide in saline) or 2-chloro-N6-cyclopentyladenosine
(CCPA; Sigma Aldrich, St Louis, Mo) by intravenous injection 5 minutes
before ischemia. CCPA is a highly selective and potent A1R agonist (affin-
ity Ki value, 0.4 and 3900 nM for rat A1R and A2AR, respectively), and
CCPA is nearly 10,000-fold more selective for A1R than for A2AR.
14
The Institutional Animal Care and Use Committee at the University of Vir-
ginia approved all animal procedures and protocols used in the present
study, which conformed to the National Institute of Health guidelines
(Guide for the Care and Use of Laboratory Animals).
Lung IR Model
The IR group underwent 1 hour of left lung ischemia and 2 hours of re-
perfusion (IR) using an established in vivo hilar clamp model.6,8 The sham
group underwent anesthesia, left thoracotomy (without the hilar clamp),
and 2 hours of reperfusion. Analgesia was administered to all the mice
after surgery.
Lung Function Measurement
After reperfusion, pulmonary function was evaluated using an isolated,
buffer-perfused lung system (Hugo Sachs Electronik, March-Huggstetten,
Germany), as previously described by our laboratory.8 After a 5-minute
equilibration period, data regarding the pulmonary arterial pressure, pul-
monary compliance, and airway resistance were recorded for an additional
5 minutes using the Pulmodyn data acquisition system (Hugo Sachs
Elektronik).
Bronchoalveolar Lavage
After lung function was measured, left lungs were lavaged with 0.4 mL
saline. The bronchoalveolar lavage (BAL) fluid was then centrifuged (1500
rpm for 8 minutes) and stored at 80C.The Journal of Thoracic and CarLung Weight/Dry Weight Ratio
Using separate groups of mice (n ¼ 6/group), the left lung was excised
after the reperfusion period, blotted dry, and immediately weighed and des-
iccated until a stable dry weight was reached. The lung wet/dry weight ratio
was calculated as a measure of lung edema.
Analysis of Cytokines and Myeloperoxidase
Cytokines weremeasured in BALfluid using amouse Bio-plex cytokine
assay (Bio-Rad Laboratories, Hercules, Calif), as previously reported.6,8
The myeloperoxidase (MPO) levels were measured in BAL fluid using
a mouse MPO enzyme-linked immunosorbent assay kit (Hycult Biotech,
Uden, The Netherlands). MPO is abundant in the azurophilic granules of
polymorphonuclear neutrophils and was used as an indicator of neutrophil
activation and infiltration into alveolar airspaces.
Chemotaxis Assay
In vitro migration was assessed in bone marrow–derived murine neu-
trophils using a commercially available kit (QCM 5-mm Chemotaxis Cell
Migration Assay; Millipore, Billerica, Mass). In brief, bone marrow cells
were harvested from mouse femurs and tibias by flushing with 10 mL of
phosphate-buffered saline containing 10% fetal bovine serum (FBS). The
suspended cells were centrifuged at 500g for 10 minutes. After red blood
cell lysis for 2 minutes at room temperature, the cells were washed,
counted, and resuspended in Roswell Park Memorial Institute buffer.
Neutrophil isolation was then performed using a commercially available
anti-Ly-6G mouse microbead kit (Miltenyi Biotech, Bergisch Gladbach,
Germany), according to the manufacturer’s instructions. The neutrophils
were resuspended at 2 3 106 cells/mL in Roswell Park Memorial Insti-
tute buffer with 0.5% FBS, and 250 mL of the cell suspension was incu-
bated in a 5-mm insert, with or without A1R agonist CCPA (10 ng/mL),
for 30 minutes at 37C. Next, 500 mL of serum-free medium was then
added to the lower chamber, with or without chemoattractant (10%
FBS), and the plate was incubated for 4 hours at 37C in a carbon dioxide
incubator. After the incubation period, the upper chamber was removed,
and the insert was incubated in 400 mL of cell stain for 20 minutes at
room temperature. Nonmigratory cells were removed from the interior
of the insert with a cotton swab, and the insert was transferred to
a new well containing 200 mL of extraction buffer for 15 minutes. Color-
imetric measurement of the reaction was performed at 570 nm in a plate
reader (Quant; Bio-Tek Instruments, Winooski, Vt). Two independent
in vitro experiments were performed.
Statistical Analysis
The results were analyzed using 2-way analysis of variance to determine
whether significant differences existed between the 2 groups. Comparisons
between the 2 groups were analyzed using unpaired Student t test. Data are
expressed as the mean  standard deviation.RESULTS
A1R Activation Improves Lung Function After IR
To measure the effects of exogenous A1R activation on
pulmonary function after IR, WTand A1R/mice under-
went lung IR after pretreatment with vehicle (0.1% di-
methyl sulfoxide) or CCPA (A1R agonist, 0.1, 1, and 2
mg/kg). Lung function was assessed after 2 hours of reper-
fusion. IR in the vehicle-treated mice significantly in-
creased the pulmonary artery pressure and airway
resistance and significantly decreased pulmonary compli-
ance (Figure 1). Treatment of WT mice with 1 or 2 mg/kg
CCPA resulted in significantly decreased pulmonary arterydiovascular Surgery c Volume 145, Number 6 1655
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FIGURE 1. Lung function after ischemia–reperfusion (IR) is significantly
improved by 2-chloro-N6-cyclopentyladenosine (CCPA). Wild-type (WT)
and congenic A1 receptor knockout (A1R/) mice were treated with ve-
hicle or CCPA (doses in mg/kg shown in parentheses) before ischemia. In
WTmice after IR, CCPA significantly decreased pulmonary artery pressure
and airway resistance and increased pulmonary compliance. Lung function
in A1R/ mice after IR was not significantly different from that of WT
mice after IR, and CCPA did not significantly affect the lung function in
A1R/ mice. The lung function was similar between WT and A1R/
mice after sham surgery (data not shown). *P< .03 versus WT sham,
#P<.03 versus WT IR. Data presented as mean  standard deviation.
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FIGURE 2. Pulmonary edema after ischemia–reperfusion (IR) is signifi-
cantly reduced by 2-chloro-N6-cyclopentyladenosine (CCPA). Lung wet/
dry weight ratio was measured after IR or sham surgery in congenic A1 re-
ceptor knockout (A1R/) mice and wild-type (WT)mice treated with ve-
hicle or CCPA (doses in mg/kg shown in parentheses) before ischemia.
Lung wet/dry weight ratio was significantly increased after IR in WT
mice, which was significantly attenuated by CCPA treatment. Lung wet/
dry weight ratio after IR was also elevated in A1R/mice after IR similar
to that inWTmice after IR. Lung wet/dry weight ratio was similar between
WTandA1R/mice after sham surgery (data not shown). *P<.05 versus
WT sham, #P<.05 versus WT IR. Data presented as mean standard de-
viation shown.
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Xpressure and airway resistance and significantly increased
pulmonary compliance after IR. The lung function in the
A1R/ mice after IR was impaired similarly to that in
the WTmice after IR; however, CCPA had no protective ef-
fects in the A1R/ mice after IR (Figure 1). This demon-
strates the specificity of the agonist for A1R. No significant
differences in lung function were found between the WT
and A1R/ sham mice (data not shown); thus, only data
from WT sham mice have been reported for the subsequent
experiments.1656 The Journal of Thoracic and Cardiovascular SurActivation of A1R Reduced Lung Edema After IR
To evaluate the effects of exogenous A1R activation on
lung edema after IR, the lung wet/dry weight ratio was mea-
sured in mice pretreated with vehicle or CCPA (0.1, 1, and 2
mg/kg). The WT mice had a significantly greater wet/dry
weight ratio after IR compared with the sham group
(Figure 2), which was significantly decreased by CCPA
(all doses). The lung wet/dry weight ratio after IR was
also elevated in the A1R/ mice, similar to that of the
WT mice after IR (Figure 2).A1R Activation Attenuated Proinflammatory
Cytokine Expression After IR
To measure the lung inflammatory response after IR,
the levels of proinflammatory cytokines and chemokines
were measured in the BAL fluid of mice pretreated with
vehicle or CCPA (0.1, 1, and 2 mg/kg). IR in the
vehicle-treated WT mice resulted in significantly in-
creased levels of interleukin-6, CXCL1, CCL2, and tumor
necrosis factor (TNF)-a compared with the sham mice
(Figure 3). Treatment with 2 mg/kg CCPA significantly
reduced the levels of interleukin-6, CXCL1, and CCL2
compared with WT mice after IR. TNF-a was also re-
duced by CCPA, but this did not reach statisticalgery c June 2013
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FIGURE 3. Expression of proinflammatory cytokines after ischemia–re-
perfusion (IR) is attenuated by 2-chloro-N6-cyclopentyladenosine
(CCPA). Cytokine levels in bronchoalveolar lavage fluid after IR or sham
surgery was measured in congenic A1 receptor knockout (A1R/) mice
and wild-type (WT) mice treated with vehicle or CCPA (doses in mg/kg
are shown in parentheses) before ischemia. Expression of interleukin-6
(IL-6), CXCL1, CCL2, and tumor necrosis factor-a (TNF-a) were all sig-
nificantly increased after IR in WT mice; CCPA treatment significantly
attenuated cytokine levels after IR. Cytokine levels after IR were elevated
in A1R/ mice after IR similar to those in WT mice after IR. *P<.05
versus WT sham, #P < .05 versus WT IR. Data presented as
mean  standard deviation. nd, Not detectable.
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FIGURE 4. Myeloperoxidase (MPO) levels after ischemia–reperfusion
(IR) are significantly reduced by 2-chloro-N6-cyclopentyladenosine
(CCPA). MPO levels in bronchoalveolar lavage fluid, as an estimate of neu-
trophil infiltration into alveolar airspaces, after IR or sham surgery were
measured in congenic A1 receptor knockout (A1R/) mice and in wild-
type (WT) mice treated with vehicle or CCPA (doses in mg/kg are shown
inparentheses) before ischemia. ElevatedMPO inWTmice after IRwas sig-
nificantly attenuated by CCPA. MPO levels were also elevated in A1R/
mice after IR similar to those in WT mice after IR. *P<.05 versus WT
sham, #P<.05 versusWT IR. Data presented asmean standard deviation.
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Xsignificance (P ¼ .069). Similar to lung function and the
wet/dry weight ratio, the A1R/ mice after IR had ele-
vated levels of cytokines comparable to that of the WT
mice after IR (Figure 3).The Journal of Thoracic and CarActivation of A1R Reduces MPO Levels After IR
MPO was measured in BAL fluid as an indication of neu-
trophil activation and infiltration into the alveolar airspaces.
Vehicle-treated WTmice after IR had significantly elevated
MPO levels compared with the shammice (Figure 4). Treat-
ment with 1 or 2 mg/kg CCPA significantly reduced the
MPO levels after IR to levels similar to those in the sham
group. The A1R/ mice had elevated MPO levels after
IR comparable to those of the WT mice (Figure 4).
A1R Agonist Impairs Neutrophil Chemotaxis
To evaluate a possible direct effect of A1R activation on
neutrophil migration, in vitro neutrophil chemotaxis was
evaluated using the Boyden chamber method, as described
in the ‘‘Methods’’ section. Bone marrow–derived neutro-
phils exposed to 10% FBS as a chemoattractant demon-
strated significant chemotaxis (Figure 5). Incubation of
neutrophils with CCPA (10 ng/mL, 30 minutes before stim-
ulation) significantly attenuated the chemotaxis (Figure 5).
DISCUSSION
Studies on the effects of A1R activation in IR have been
controversial. Evidence has been shown for an anti-
inflammatory role for A1R in the lung,
5 liver,15 kidney,16diovascular Surgery c Volume 145, Number 6 1657
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FIGURE 5. Neutrophil chemotaxis was significantly reduced by
2-chloro-N6-cyclopentyladenosine (CCPA). Chemotaxis was measured
in murine bone marrow–derived neutrophils, as described in the
‘‘Methods’’ section. Chemotaxis was significantly increased in medium
containing 10% fetal bovine serum (FBS) and significantly reduced by
10 ng/mL CCPA. *P< .001 versus medium, #P ¼ .03 versus medium
plus 10% FBS. Data presented as mean  standard deviation.
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Xheart,17 intestine,18 and skeletal muscle.19 However, other
studies have suggested that A1R antagonism has beneficial
effects in lung and heart IRmodels.10,20 In the present study,
we used an in vivo hilar clamp model in WT and A1R/
mice to clarify a protective role of exogenous activation
of A1R in lung IR injury. Our results have demonstrated
the anti-inflammatory effects of CCPA, a potent and selec-
tive A1R agonist, against lung IR injury. The parameters of
lung injury, dysfunction, and inflammation showed a signif-
icant dose-dependent improvement after exogenous A1R
activation. These results are in agreement with other reports
of improved lung function after A1R activation in acute lung
injury models.5,21
In addition to defining a protective role of exogenous A1R
activation in lung IR injury, our results have provided insight
into the potential mechanisms for A1R-mediated anti-
inflammatory effects. One mechanism of lung protection
by A1R agonist is the modulation of cytokines and chemo-
kines, which are important for the recruitment and activation
of effector cells such as neutrophils. In the present study,
CCPA attenuated the levels of several proinflammatory cy-
tokines/chemokines after IR, including interleukin-6,
CXCL1 (KC), CCL2 (monocyte chemotactic protein-1),
and TNF-a. This suggests that activation of A1Rs on cells
such as the alveolar epithelial cells ormacrophages could di-
rectly affect the secretion of CCL2 and TNF-a, respectively,
by these cells and that an A1R agonist, such as CCPA, can
exogenously activate A1R-mediated anti-inflammatory ef-
fects. The elevation in CXCL1, CCL2, and TNF-a in1658 The Journal of Thoracic and Cardiovascular SurA1R/ mice after IR has also been described in a model
of kidney IR injury, in which reconstitution of A1R by len-
tivirus injection encoding for the human A1R gene de-
creased CCL2 and TNF-a expression to sham levels.22
Another potential mechanism of A1R agonist-mediated
protection is the modulation of inflammatory cell recruit-
ment. Studies have shown that activation and migration of
neutrophils are crucial events that modulate the inflamma-
tion process after IR, and the important role of neutrophil re-
cruitment in lung IR injury has been demonstrated in our
laboratory.23 The results of the present study showed that
WT mice had significantly elevated MPO levels in the
BALfluid after IR and that A1R activation byCCPA reduced
theMPO levels, indicating a reduction in alveolar neutrophil
activation and recruitment. These results are in agreement
with previous studies of lung5 and kidney16 IR models.
In vitro studies have shown that the A1R agonist de-
creases albumin permeability across confluent bovine pul-
monary artery endothelial cell monolayers.24 Our present
study evaluated the direct effect of selective A1R activation
on neutrophil chemotaxis in vitro. Bone marrow–derived
neutrophils incubated with 10% FBS demonstrated in-
creased chemotaxis compared with cells incubated with
medium alone, and CCPA treatment significantly attenu-
ated neutrophil chemotaxis. These results have demon-
strated that A1R agonist can act directly on neutrophils to
impair migration.
Although we anticipated that the A1R/ mice would
haveworse lung IR injury than theWTmice, these mice dis-
played a level of injury similar to that of the WT mice.
These results could have several explanations. First, one ex-
planation might be because endogenous adenosine produc-
tion during IR can act on any or all of 4 adenosine receptors
to initiate the signaling pathways that can have synergistic
or antagonistic effects. The pharmacology of adenosine re-
ceptor signaling is complex, and the role of these individual
receptors can be proinflammatory or anti-inflammatory dur-
ing lung IR injury, as noted. Hence, in A1R/ mice, en-
dogenous adenosine could still exert an anti-inflammatory
effect by other adenosine receptors such as A3R or A2AR,
thereby preventing worse lung injury after IR. Second,
adenosine receptor signaling cascades that occur in
A1R/ mice remain unknown and could be disrupted,
and it is possible that potential crosstalk between A1R and
other adenosine receptors could be altered in A1R/
mice. Several studies have now pointed to synergistic mech-
anisms between various adenosine receptors, especially
A1R, A2AR, and A2BR. For example, Urmaliya and col-
leagues25,26 found that endogenous adenosine contributes
to A1R-mediated cardioprotection by cooperative
interactions with both A2AR and A2BR. The complex and
cooperative adenosine receptor signaling mechanisms
involved in lung IR injury remain unknown, and it is
likely that similar cooperative pathways are disrupted ingery c June 2013
Fernandez et al Cardiothoracic Transplantationthe A1R/ mice. Importantly, however, the exogenous
activation of A1R by CCPA in WT mice in the present
study clearly resulted in significant protection from lung
injury and dysfunction after IR, supporting the therapeutic
use of A1R agonists to prevent lung IR injury.CONCLUSIONS
We have demonstrated the protective, anti-inflammatory
effects of an A1R agonist in the setting of lung IR injury. Ex-
ogenous A1R activation by CCPA improved lung function
and decreased the injury and inflammation after IR. These
protective effects involved the attenuation of edema, proin-
flammatory cytokines, and the infiltration and chemotaxis
of neutrophils. These results suggest that the pharmacologic
activation of A1R by selective agonists could be a promising
strategy to prevent and/or treat lung IR injury and primary
graft dysfunction after transplantation.References
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